Advertisement

Regulation of the Immune Response by Eicosanoid Acids

Chapter
Part of the Prostaglandins, Leukotrienes, and Cancer book series (PLAC, volume 4)

Abstract

Oxygenated arachidonic acid derivatives are metabolites that issue from both the cyclooxygenase and the lipoxygenase pathways and act as important local immunoregulators. The cyclooxygenase products, especially the prostaglandins (PGs), are being thoroughly investigated with regard to their role in the immune response. Inhibition of lymphocyte activity is the main function of prostaglandins as immunoregulators, and PGE2 may be viewed as a macrophage messenger for an inhibitory signal to lymphocytes (1). It is likely that PGE2 is a biological mediator of a physiologic negative feedback mechanism following stimulation by antigens (2).

Keywords

Arachidonic Acid Mouse Peritoneal Macrophage Lipoxygenase Pathway Eicosatetraenoic Acid Lymphocyte Membrane 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Goodwin JS, Webb DR: Regulation of the immune response by prostaglandins. Clin Immunol Immunopathol (15): 106–122, 1980.PubMedCrossRefGoogle Scholar
  2. 2.
    Goodwin JS, Ceuppens JL, Gualde N: Control of the immune response in humans by prostaglandins. In: Otterness I, Capetola RJ, Wong S (eds) Therapeutic control of inflammatory diseases. Raven Press, New York, 1983, pp 79–92.Google Scholar
  3. 3.
    Rabinovitch H, Durand J, Gualde N, Rigaud M: Metabolism of polyunsaturated fatty acids by mouse peritoneal macrophages: the lipoxygenase metabolic pathway. Agents Actions (11): 580–583, 1981.PubMedCrossRefGoogle Scholar
  4. 4.
    Rigaud M, Durand J, Breton JC: Transformation of arachidonic acid into 12-hydroxy-5,8,10,14-eicosatetraenoic acid by mouse peritoneal macrophages. Biochim Biophys Acta (573): 408–412, 1979.PubMedGoogle Scholar
  5. 5.
    Samuelsson B: Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science (220): 568–575, 1983.PubMedCrossRefGoogle Scholar
  6. 6.
    Dahlén SE, Björk J, Hedqvist P, Arfors KE, Hammarström S, Lindgren JA, Samuelsson B: Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci USA (78): 3887–3891, 1981.PubMedCrossRefGoogle Scholar
  7. 7.
    Hammarström S: Leukotrienes. Annu Rev Biochem (52): 355–377, 1983.CrossRefGoogle Scholar
  8. 8.
    Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith MJH: Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature (286): 264–265, 1980.PubMedCrossRefGoogle Scholar
  9. 9.
    Goetzl EJ, Brindley LL, Goldman DW: Enhancement of human neutrophil adherence by synthetic leukotriene constituents of the slow-reacting substance of anaphylaxis. Immunology (50): 35–42, 1983.PubMedGoogle Scholar
  10. 10.
    Lewis RA, Austen KF: Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds. Nature (293): 103–108, 1981.PubMedCrossRefGoogle Scholar
  11. 11.
    Rola-Pleszczynski M, Gagnon L, Sirois P: Leukotriene B4 augments human natural cytotoxic cell activity. Biochem Biophys Res Commun (113): 531–537, 1983.PubMedCrossRefGoogle Scholar
  12. 12.
    Benjamin CW, Hopkins NK, Oglesby T, Gorman R: Against specific desensitization of leukotriene C4-stimulated PGI2 synthesis in human endothelial cells. Biochem Biophys Res Commun (117): 780–787, 1983.PubMedCrossRefGoogle Scholar
  13. 13.
    Bailey JM, Bryant RW, Low CE, Pupillo MB, Vanderhoek JY: Regulation of T lymphocyte mitogenesis by the leukocyte product 15-hydroxyeicosatetraenoic acid (15-HETE). Cell Immunol (67): 112–120, 1982.PubMedCrossRefGoogle Scholar
  14. 14.
    Vanderhoek JY, Bryant RW, Bailey JM: Inhibition of leukotriene biosynthesis by the leukocyte product 15-hydroxyeicosatetraenoic acid. J Biol Chem (255): 10064–10065, 1980.PubMedGoogle Scholar
  15. 15.
    Vanderhoek JY, Tare NS, Bailey M, Goldstein A, Pluznik D: New role for 15-hydroxyeicosatetraenoic acid. J Biol Chem (257): 12191–12195, 1982.PubMedGoogle Scholar
  16. 16.
    Crews FT, Morita Y, McGivney A, Hirata F, Siraganian RP, Axelrod J: IgE-mediated histamine release in rat basophilic leukemia cells: receptor activation, phospholipid methylation, Ca2 flux, and release of arachidonic acid. Arch Biochem Biophys (212): 561–571, 1981.PubMedCrossRefGoogle Scholar
  17. 17.
    Kelly JP, Parker CW: Effects of arachidonic acid and other unsaturated fatty acids on mitogenesis in human lymphocytes. J Immunol (122): 1556–1562, 1979.PubMedGoogle Scholar
  18. 18.
    Kelly JP, Johnson MC, Parker CW: Effect of inhibitors of arachidonic acid metabolism on mitogenesis in human lymphocytes: possible role of thromboxanes and products of the lipoxygenase pathway. J Immunol (122): 1563–1571, 1979.PubMedGoogle Scholar
  19. 19.
    Parker CW, Stenson WF, Huber MG, Kelly JP: Formation of thromboxane B2 and hydroxyarachidonic acids in purified human lymphocytes in the presence and absence of PHA. J Immunol (122): 1572–1577, 1979.PubMedGoogle Scholar
  20. 20.
    Webb DR, Nowowiejski I, Healy C, Rogers TJ: Immunosuppressive properties of leukotriene D4 and E4 in vitro. Biochem Biophys Res Commun (104): 1617–1622, 1982.PubMedCrossRefGoogle Scholar
  21. 21.
    Payan DG, Goetzl EJ: Specific suppression of human T lymphocyte function by leukotriene B4. J Immunol (131): 551–553, 1983.PubMedGoogle Scholar
  22. 22.
    Rola-Pleszczynski M, Borgeat P, Sirois P: Leukotriene B4 induces human suppressor lymphocytes. Biochem Biophys Res Commun (108): 1531–1537, 1982.PubMedCrossRefGoogle Scholar
  23. 23.
    Goodman MG, Weigle WO: Inhibition of lymphocyte mitogenesis by an arachidonic acid hydroperoxide. J Supramol Struct (13): 373–383, 1980.PubMedCrossRefGoogle Scholar
  24. 24.
    Gualde N, Rigaud M, Rabinovitch H, Durand J, Beneytout JL, Breton JC: Inhibition de la résponse lymphocytaire par les métabolites libérés par la lipoxygénase des macrophages chez la souris. C R Seances Acad Sci [III] (Paris) (293): 359–362 (Eng. Abstr.), 1981.Google Scholar
  25. 25.
    Gualde N, Chable-Rabinovitch H, Motta C, Durand J, Beneytout JL, Rigaud M: Hydroperoxyeicosatetraenoic acids-potent inhibitors of lymphocyte responses. Biochim Biophys Acta (750): 429–433, 1983.PubMedGoogle Scholar
  26. 26.
    Gualde N, Rabinovitch H, Fredon M, Rigaud M: Effects of 15-hydroperoxyeicosatetraenoic acid on human lymphocyte sheep erythrocyte rosette formation and response to Concanavalin A associated with HLA system. Eur J Immunol (12): 773–777, 1982.PubMedCrossRefGoogle Scholar
  27. 27.
    Gualde N: Les métabolites oxygénés de l’acide arachidonique et l’activité des lymphocytes. PhD thesis in immunology, Université Paris VI, Paris, 1983.Google Scholar
  28. 28.
    Gualde N, Goodwin JS, Chable-Rabinovitch H, Beneytout JL, Shinitzki M, Rigaud M: Fifth international congress of immunology, Kyoto, 1983.Google Scholar
  29. 29.
    Goodwin JS, Gualde N, Aldigier J, Rigaud M, Vanderhoek JY: Modulation of Fcy receptors on T cells and monocytes by 15 hydroperoxyeicosatetraenoic acid. Prostaglandins Med (13): 109–112, 1984.CrossRefGoogle Scholar
  30. 30.
    Gualde N: First international workshop on lipoxygenase and animal tissues, Limoges, 1983.Google Scholar
  31. 31.
    Aldigier JC, Gualde N, Mexmain S, Chable-Rabinovitch H, Ratinaud MH, Rigaud M: Immunosuppression induced in vivo by 15 hydroxyeicosatetraenoic acid (15 HETE). Prostaglandins Med (13): 99–107, 1984.CrossRefGoogle Scholar
  32. 32.
    Gualde N, Rigaud M, Goodwin JS: Induction of suppressor cells from human peripheral blood T cells by 15 hydroperoxyeicosatetraenoic acid (15 HPETE). Clin Res (31): 490A, 1983.Google Scholar
  33. 33.
    Mexmain S, Gualde N, Aldigier JC, Motta C, Chable-Rabinovitch H, Rigaud M: Specific binding of 15 HETE to lymphocytes. Effects on the fluidity of plasmatic membranes. Prostaglandins Med (13): 93–97, 1984.CrossRefGoogle Scholar
  34. 34.
    Rola-Pleszczynski M, Gagnon L, Sirois P: International meeting on eicosanoids and cancer, Bandor, 1983.Google Scholar
  35. 35.
    Salmon JA, Smith DR, Flower RJ, Moncada S, Vane JR: Further studies on the enzymatic conversion of prostaglandin endoperoxide into prostacyclin by porcine aorta microsomes. Biochim Biophys Acta (523): 250–262, 1978.PubMedGoogle Scholar
  36. 36.
    Honn KV, Busse WD, Sloane BF: Prostacyclin and thromboxanes -implications for their role in tumor cell metastasis. Biochem Pharmacol (32): 1–11, 1983.PubMedCrossRefGoogle Scholar
  37. 37.
    Harbon S, Leiber D, Vesin M-F: Phospholipase A2 activation coupled to lipoxygenase and cyclooxygenase pathways in the guinea pig myometrium: interaction with the cyclic AMP and cyclic GMP systems. In: Samuelsson B, Paoletti R, Ramwell PW (eds) Advances in prostaglandin, thromboxane, and leukotriene research, Vol. 12. Raven Press, New York, 1983, pp 423–428.Google Scholar
  38. 38.
    Strom TB, Lundin AP, Carpenter CB: The role of cyclic nucleotides in lymphocyte activation and function. In: Schwartz RS (ed) Progress in clinical immunology, Vol. 3. Grune and Stratton, New York, 1977, pp 115–153.Google Scholar
  39. 39.
    Gualde N, Mexmain S, Aldigier JC, Goodwin JS, Rigaud M: Eicosanoids and the immune response. In: Craste de Paulet J (ed) Eicosanoids and cancer. Raven Press, New York, in press.Google Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1985

Authors and Affiliations

There are no affiliations available

Personalised recommendations